rs1064608 — MTCH2 Pro290Ala

MTCH2 Pro290Ala — When Your Mitochondria Struggle to Choose Their Fuel

The mitochondria in your cells do not burn a fixed fuel. Depending on what you have eaten, your activity level, and the time of day, they switch between glucose and fatty acids — a flexibility that is central to healthy metabolism and, it turns out, to restorative sleep. MTCH2 (mitochondrial carrier homolog 2¹¹ mitochondrial carrier homolog 2
an outer mitochondrial membrane protein that regulates fuel switching and fusion dynamics) sits at this switching point. The Pro290Ala variant (rs1064608 C allele) subtly shifts how efficiently MTCH2 performs this role, with downstream effects on body weight, energy regulation, and sleep quality.

The Mechanism

MTCH2 is embedded in the outer mitochondrial membrane and performs two linked functions. First, it regulates carnitine palmitoyltransferase 1 (CPT1), the gate-keeping enzyme that determines how much fatty acid enters the mitochondrion for oxidation. When MTCH2 is functioning normally, it fine-tunes CPT1's sensitivity to malonyl-CoA — a metabolite that signals "enough fat is being burned, slow down." A functional change in MTCH2 shifts this gate, reducing fatty acid oxidation ²² Wu et al., MTCH2 modulates CPT1 activity to regulate lipid metabolism of adipocytes, Nat Commun 2025.

Second, MTCH2 promotes mitochondrial fusion during nutrient stress. When fuel is scarce, mitochondria normally elongate (hyperfuse) to extract more energy from available substrates. MTCH2 enables this response by coupling lipid synthesis flux to the fusion machinery via lysophosphatidic acid signaling ³³ Labbé et al., MTCH2 links mitochondrial fusion to lipogenesis, J Cell Biol 2021. The Pro290Ala substitution changes a conserved proline in a transmembrane helix, likely affecting the protein's conformational flexibility and its interaction with CPT1 and fusion proteins.

The Evidence

The MTCH2 locus at chromosome 11 first emerged as a significant obesity signal in 2009, when Willer et al. conducted a GWAS in >91,000 individuals and identified six new BMI loci — TMEM18, KCTD15, GNPDA2, SH2B1, MTCH2, and NEGR1⁴⁴ when Willer et al. conducted a GWAS in >91,000 individuals and identified six new BMI loci — TMEM18, KCTD15, GNPDA2, SH2B1, MTCH2, and NEGR1
Willer CJ et al., Six new loci associated with body mass index, Nature Genetics 2009. MTCH2 was notable because the associated variants also implicated neuronal pathways, consistent with central regulation of energy balance.

In 2019, the largest insomnia GWAS to date — 1,331,010 individuals across multiple cohorts⁵⁵ 1,331,010 individuals across multiple cohorts
Jansen PR et al., Genome-wide analysis of insomnia, Nature Genetics 2019 — identified 202 loci enriched in genes expressed in hypothalamic and striatal neurons. The MTCH2 chromosomal region appeared among these loci, connecting the mitochondrial fuel-switching biology to the neuronal circuits that regulate sleep-wake transitions.

The functional mechanism was clarified by Fischer et al. 2023⁶⁶ Fischer et al. 2023
Fischer JA et al., Opposing effects of genetic variation in MTCH2 for obesity versus heart failure, Hum Mol Genet 2023, who showed that the Pro290 allele (G; the reference) associates with reduced MTCH2 expression via an eQTL (rs10838738), impaired glucose oxidation, and higher lactate production — but paradoxically lower BMI. The Ala290 allele (C), carried by about 35% of Europeans, is the higher-BMI genotype. Importantly, this study also identified a cardiac liability: reduced MTCH2 function (Pro290/lower expression) is overrepresented in cardiomyopathy cases, highlighting that the same gene variant has metabolically opposing effects depending on whether the tissue relies primarily on fatty acids (skeletal muscle, resting heart) or glucose (stressed heart).

The sleep connection is biologically coherent: hypothalamic neurons that control sleep-wake cycling depend on precise mitochondrial ATP production. When fuel switching is impaired, these neurons sustain suboptimal energy delivery during the early-morning hours when the body increases metabolic demand before waking — a window where mitochondrial efficiency is most critical for sleep consolidation.

Practical Actions

For carriers of one or two C alleles (Ala290), the actionable priority is supporting mitochondrial metabolic flexibility. Ubiquinol (the active form of CoQ10) directly supports the electron transport chain and has the strongest evidence for mitochondrial supplementation. Acetyl-L-carnitine supports CPT1-mediated fatty acid entry into mitochondria — a pathway MTCH2 variants specifically affect. Time-restricted eating windows of 8–10 hours help synchronize mitochondrial fuel cycling with circadian rhythms, reducing the metabolic load on MTCH2-dependent switching overnight.

For those with two C alleles, metabolic monitoring (fasting glucose, insulin, HbA1c) is warranted, given the documented link between MTCH2 impairment and glucose oxidation deficits.

Interactions

The MTCH2 locus shows genetic correlation with FTO (rs1421085, rs9939609), which independently affects fat mass and appetite regulation. Carrying risk alleles at both loci compounds adiposity risk beyond what either gene predicts alone — a compound action covering both genotypes would be appropriate if strong evidence of interaction exists. MTCH2 also sits in a pathway with PPARGC1A (PGC-1alpha), the master regulator of mitochondrial biogenesis; variants that reduce both MTCH2 function and PGC-1alpha expression may synergistically impair mitochondrial capacity.